Your browser is no longer supported. Please, upgrade your browser.
Settings
DARE Dare Bioscience, Inc. daily Stock Chart
DARE [NASD]
Dare Bioscience, Inc.
Index- P/E- EPS (ttm)-2.03 Insider Own20.60% Shs Outstand10.99M Perf Week11.01%
Market Cap13.30M Forward P/E- EPS next Y-0.66 Insider Trans- Shs Float9.07M Perf Month34.46%
Income-11.50M PEG- EPS next Q-0.23 Inst Own31.30% Short Float9.41% Perf Quarter-12.32%
Sales- P/S- EPS this Y-341.80% Inst Trans274.77% Short Ratio0.73 Perf Half Y-48.29%
Book/sh2.19 P/B0.55 EPS next Y- ROA-74.70% Target Price15.00 Perf Year-69.09%
Cash/sh0.69 P/C1.75 EPS next 5Y- ROE-96.80% 52W Range0.74 - 12.40 Perf YTD-44.09%
Dividend- P/FCF- EPS past 5Y25.50% ROI- 52W High-90.24% Beta2.77
Dividend %- Quick Ratio8.60 Sales past 5Y- Gross Margin- 52W Low63.45% ATR0.14
Employees19 Current Ratio8.60 Sales Q/Q- Oper. Margin- RSI (14)59.42 Volatility10.85% 15.57%
OptionableNo Debt/Eq0.00 EPS Q/Q-559.30% Profit Margin- Rel Volume0.80 Prev Close1.16
ShortableYes LT Debt/Eq0.00 EarningsJul 02 AMC Payout- Avg Volume1.17M Price1.21
Recom1.00 SMA2011.45% SMA5020.34% SMA200-44.45% Volume939,157 Change4.22%
May-16-18 08:00AM  EY Announces that Sabrina Martucci Johnson, CEO of Daré Bioscience, Inc., is an Entrepreneur Of The Year® 2018 Award Finalist in San Diego GlobeNewswire
May-15-18 08:00AM  Daré Bioscience, Inc. Announces Trial Initiation for Ovaprene® Non-Hormonal Monthly Contraceptive Candidate GlobeNewswire
May-08-18 08:00AM  Daré Bioscience, Inc. Expands Leadership Team, Appointing John Fair to Chief Business Officer GlobeNewswire -8.73%
May-07-18 08:00AM  Daré Bioscience, Inc. Enters into Agreement to Acquire Product to Address Vulvar and Vaginal Atrophy in Hormone Receptor-Positive Breast Cancer Patients GlobeNewswire +10.59%
Apr-30-18 08:00AM  Daré Bioscience announces funding award to further the development of Ovaprene from the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) GlobeNewswire +7.82%
Apr-26-18 08:10AM  Todays Research Reports on Stocks to Watch: Dare Bioscience and ACADIA ACCESSWIRE
Apr-25-18 08:00AM  Daré Bioscience, Inc. Enters into Exclusive Worldwide License Agreement for Juniper Pharmaceuticals Intravaginal Ring (IVR) Technology Platform GlobeNewswire +56.69%
Apr-13-18 07:20AM  Blog Exposure - BiondVax Pharma Initiated NIH-Sponsored Phase-2 Clinical Trial of M-001 in the US ACCESSWIRE
Apr-11-18 08:00AM  Jessica Grossman, M.D., Joins Daré Bioscience Board of Directors GlobeNewswire
Apr-02-18 04:05PM  Daré Bioscience, Inc. Reports 2017 Financial Results and Provides Business Update GlobeNewswire
12:15PM  Dare Bioscience, Inc. to Host Earnings Call ACCESSWIRE
Mar-29-18 08:30AM  Daré Bioscience, Inc. to Announce Full Year 2017 Financial Results and Host a Live Conference Call and Webcast on Monday, April 2, 2018 GlobeNewswire
Mar-12-18 08:00AM  Daré Bioscience Announces Exclusive Development and Option Agreement with Orbis Biosciences for Long-acting Injectable Contraceptive GlobeNewswire
Mar-05-18 08:00AM  Daré Bioscience, Inc. To Participate in the 30th Annual ROTH Conference GlobeNewswire
Feb-27-18 08:00AM  Daré Bioscience, Inc. To Participate in the LD Micro Virtual Conference GlobeNewswire -5.15%
Feb-26-18 08:10AM  Daré Bioscience, Developing Products for Women, Analysts Target, Pipeline Review ACCESSWIRE
Feb-15-18 11:06AM  Daré Bioscience, Inc. Announces Effective License and Collaboration Agreement for Topical Sildenafil for Female Sexual Arousal Disorder GlobeNewswire
Feb-13-18 09:18AM  Daré Bioscience, Inc. to raise approximately $10.25 million GlobeNewswire -39.78%
08:30AM  Todays Research Reports on Trending Tickers: Dare Bioscience and MannKind ACCESSWIRE
Feb-12-18 08:57PM  Daré Bioscience, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire +50.00%
08:00AM  Daré Bioscience, Inc. Enters into License and Collaboration Agreement for a Product with the Potential to Receive the First FDA Approval for Female Sexual Arousal Disorder GlobeNewswire
Feb-06-18 08:00AM  Daré Bioscience, Inc. to Present at the 2018 BIO CEO & Investor Conference GlobeNewswire +7.37%
Jan-10-18 09:01AM  Sabrina Martucci Johnson Joins Aethlon Medical's Board of Directors PR Newswire
Dec-08-17 07:03PM  Who Are The Major Shareholders Of Daré Bioscience Inc (DARE)? Simply Wall St. +9.17%
Dec-04-17 08:00AM  Daré Bioscience, Inc. to Present at the LD Micro 10th Annual Main Event Conference GlobeNewswire
Nov-30-17 01:05PM  With An ROE Of 177.59%, Has Daré Bioscience Incs (DARE) Management Done A Good Job? Simply Wall St.
Oct-20-17 09:56AM  Daré Bioscience Inc (DARE): Is Healthcare Attractive Relative To NasdaqCM Peers? Simply Wall St.
Oct-10-17 08:30AM  Daré Bioscience, Inc. to Present at the 2017 BIO Investor Forum GlobeNewswire
Sep-07-17 08:30AM  Daré Bioscience, Inc. to Present at the 19th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire
Aug-30-17 08:30AM  Daré Bioscience, Inc. to Present at the Liolios 6th Annual Gateway Conference GlobeNewswire
Aug-15-17 08:30AM  Daré Bioscience, Inc. CEO Featured in San Diego Business Journal Article on Women Founders GlobeNewswire
Dare Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder. The company has license and collaboration agreement with Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC to develop and commercialize indications for women related to female sexual dysfunction and/or female reproductive health. The company was incorporated in 2005 and is headquartered in La Jolla, California.